Identification of the molecular requirements for an RARα-mediated cell cycle arrest during granulocytic differentiation

Blood

Volumn 103, Issue 4, 2004, Pages 1286-1295

  Walkley, Carl R ^b   Purton, Louise E ^b   Snelling, Hayley J ^b   Yuan, Yang Dar ^b   Nakajima, Hideaki ^b   Chambon, Pierre ^b   Chandraratna, Roshantha A S ^b   McArthur, Grant A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; MYC PROTEIN; PROTEIN MAD1; PROTEIN P27; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID;

ADOLESCENT; ANIMAL CELL; ARTICLE; BIOASSAY; BONE MARROW; CCAAT ENHANCER BINDING PROTEIN EPSILON GENE; CELL CYCLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; GENE; GENE INDUCTION; GRANULOPOIESIS; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN INDUCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0842285679     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2391     Document Type: Article

References (58)

1. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
2. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
3. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
4. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940-954.
5. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454-457.
6. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569-580.
7. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354-1357.
8. Torchia J, Rose DW, Inostroza J, et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997;387:677-684.
9. Labrecque J, Allan D, Chambon P, Iscove NN, Lohnes D, Hoang T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alphal and gamma. Blood. 1998;92:607-615.
10. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
11. Robertson KA, Emami B, Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood. 1992;80:1885-1889.
12. Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000;6:25-58.
13. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
14. McArthur GA, Laherty C, Queva C, et al. The MAD protein family links transcriptional repression to cell differentiation. Cold Spring Harb Symp Quant Biol. 1998;LXIII:423-433.
15. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10:142-153.
16. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82:675-684.
17. McArthur GA, Foley KP, Fero ML, et al. MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. Mol Cell Biol. 2002;22:3014-3023.
18. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic: acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002;99:2199-2206.
19. Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J. 1998;17:774-785.
20. Beard R, Duong T, Teng M, Klein E, Standevan A, Chandraratna R. Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002;12:3145-3148.
21. Teng M, Duong TT, Johnson AT, et al. Identification of highly potent retinoic acid receptor alpha-selective antagonists. J Med Chem. 1997;40:2445-2451.
22. Johnson AT, Wang L, Standeven AM, Escobar M, Chandraratna RA. Synthesis and biological activity of high-affinity retinoic acid receptor antagonists. Bioorg Med Chem. 1999;7:1321-1338.
23. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996;85:733-744.
24. Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell. 1993;73:643-658.
25. Lufkin T, Lohnes D, Mark M, et al. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A. 1993;90:7225-7229.
26. Walkley CR, Yuan YD, Chandraratna RA, McArthur GA. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia. 2002;16:1763-1772.
27. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988;18:97-104.
28. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A. 1993;90:7153-7157.
29. El-Osta A, Wolffe AP. Analysis of chromatin-immunopurified MeCP2-associated fragments. Biochem Biophys Res Commun. 2001;289:733-737.
30. Jacobsen SE, Fahlman C, Blomhoff HK, Okkenhaug C, Rusten LS, Smeland EB. All-trans- and 9-cis-retinoic acid: potent direct inhibitors of primitive murine hematopoietic progenitors in vitro. J Exp Med. 1994;179:1665-1670.
31. Lawson ND, Krause DS, Berliner N. Normal neutrophil differentiation and secondary granule gene expression in the EML and MPRO cell lines. Exp Hematol. 1998;26:1178-1185.
32. Lian Z, Wang L, Yamaga S, et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood. 2001;98:513-524.
33. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996;271:1861-1864.
34. Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D. Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. J Biol Chem. 2001;276:45945-45951.
35. Alessandrini A, Chiaur DS, Pagano M, Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 1997;11:342-345.
36. Park DJ, Chumakov AM, Vuong PT, et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest. 1999;103:1399-1408.
37. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem. 1996;271:3891-3896.
38. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273:28545-28548.
39. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in ccaat enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A. 1997;94:569-574.
40. Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A. 1997;94:13187-13192.
41. Yamanaka R, Kim GD, Radomska HS, et al. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci U S A. 1997;94:6462-6467.
42. Truong BT, Lee YJ, Lodie TA, et al. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood. 2003;101:1141-1148.
43. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia. 2003;17:1723-1730.
44. Park DJ, Vuong PT, De Vos S, Douer D, Koeffler HP. Comparative analysis of genes regulated by PML/RARα and PLZF/RARα in response to retinoic acid using oligonucleotide arrays. Blood. 2003;102:3727-3736.
45. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115-1129.
46. kip1 and the timing of oligodendrocyte differentiation. EMBO J. 1997;16:306-317.
47. cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2001;2:27-34.
48. Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science. 1991;251:288-292.
49. Flodby P, Barlow C, Kylefjord H, Ahrlundrichter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in ccaat/enhancer binding protein alpha. J Biol Chem. 1996;271:24753-24760.
50. O'Rourke J, Yuan R, Dewille J. Ccaat/enhancer-binding protein-delta (C/EBP-δ) is induced in growth-arrested mouse mammary epithelial cells. J Biol Chem. 1997;272:6291-6296.
51. Tanaka T, Yoshida N, Kishimoto T, Akira S. Defective adipocyte differentiation in mice lacking the C/EBPβ and/or C/EBPδ gene. EMBO J. 1997;16:7432-7443.
52. Porse BT, Pedersen TA, Xu X, et al. E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell. 2001;107:247-258.
53. Wang H, Iakova P, Wilde M, et al. C/EBPα arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 2001;8:817-828.
54. Wang H, Goode T, lakova P, Albrecht JH, Timchenko NA. C/EBPα triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J. 2002;21:930-941.
55. Nakajima H, Ihle JN. Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT/enhancer-binding protein epsilon. Blood. 2001;98:897-905.
56. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
57. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
58. Rizvi NA, Marshall JL, Ness E, et al. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002;20:3522-3532.